Edition:
India

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.64USD
2:29am IST
Change (% chg)

$0.02 (+1.23%)
Prev Close
$1.62
Open
$1.59
Day's High
$1.64
Day's Low
$1.59
Volume
17,109
Avg. Vol
28,741
52-wk High
$5.69
52-wk Low
$1.56

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics Q3 loss per share $1.35
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces third quarter 2017 financial results.Q3 loss per share $1.35.Q3 revenue $18.9 million.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

Orexigen Therapeutics - pursuing potential actions including merger or sale of co
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​.Orexigen Therapeutics-‍management evaluating whether there are relevant conditions to raise substantial doubt about co's ability to continue as going concern​.Orexigen Therapeutics-in connection with evaluation, ‍co currently pursuing number of potential actions, including attempting to pursue merger or sale of co.  Full Article

Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Orexigen Therapeutics Inc ::Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030.Orexigen therapeutics - U.S. Court issued ruling in favor of Orexigen in litigation against Actavis Laboratories FL inc for three patents for Contrave​.  Full Article

Valeant acquires Canadian rights for Contrave in treatment of obesity
Tuesday, 30 Aug 2016 

Valeant Pharmaceuticals International Inc : Valeant acquires the Canadian rights for Contrave® in the treatment of obesity . Valeant expects to file with health Canada for regulatory approval by January 2017 . Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses . Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016 .Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave
Tuesday, 30 Aug 2016 

Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave® (naltrexone hcl / bupropion hcl extended release).  Full Article

Orexigen Therapeutics announces Q2 loss per share $1.73
Friday, 5 Aug 2016 

Orexigen Therapeutics Inc : Orexigen Therapeutics reports business and financial results for the second quarter ended June 30, 2016 . Q2 revenue $7.8 million versus I/B/E/S view $6.9 million . Q2 loss per share $1.73 .Q2 earnings per share view $-1.47 -- Thomson Reuters I/B/E/S.  Full Article

Orexigen Therapeutics unit, ROVI announce agreement
Monday, 1 Aug 2016 

Orexigen Therapeutics Inc : "Expect mysimba to contribute to group's revenue in next few years" . Unit, Laboratorios Farmacéuticos Rovi S.A. executed commercialization and distributorship agreement for mysimba .Rovi expects to begin marketing mysimba by year-end 2016.  Full Article

Orexigen Therapeutics announces a 1-for-10 reverse stock split
Saturday, 9 Jul 2016 

Orexigen Therapeutics Inc : Orexigen therapeutics announces stockholder approval of all proposals at 2016 annual meeting and reverse stock split . Also announced a 1-for-10 reverse stock split .Expects that shares of orexigen will begin trading on a post-split basis on july 12, 2016.  Full Article

Orexigen Therapeutics Inc announces strategic acquisition of all U.S. rights to Contrave
Tuesday, 15 Mar 2016 

Orexigen Therapeutics Inc:Says entered into an agreement with Takeda Pharmaceutical Company Limited to acquire United States rights to Contrave.At the closing, Orexigen will pay Takeda $60 million to acquire Contrave U.S. rights.Following completion of transition period, Orexigen is required to pay Takeda an additional $15 million in first quarter 2017.Orexigen is also required to pay Takeda milestone payments upon achievement of certain levels of U.S. net sales of Contrave, the first of which, a $10 million payment, occurs when Contrave net sales reach $200 million in any calendar year.  Full Article

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results